Antibiotic-induced gut dysbiosis has been associated with poor outcomes after intensive therapy. We evaluated the effect of levofloxacin (LEVO), the most commonly used prophylactic antibacterial antibiotic during intensive chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT), on the gut microbiota in 2 cohorts of patients, 1 cohort comprising 20 patients with acute leukemia receiving intensive chemotherapy and the other cohort comprising 20 allo-HCT recipients. 16S rRNA gene sequencing of thrice-weekly collected stool samples permitted a comparison between intervals with no antibacterial antibiotic exposure and those with only LEVO exposure. In mixed-effects modeling, the only variables influenced by LEVO were the relative abundances of Parabacteroides (regression coefficient, -.063; 99% confidence interval [CI], -.102 to -.024) and Blautia (regression coefficient, .050; 99% CI, .004 to .095). Other taxa and microbiota diversity were unaffected. Overall, the effect of LEVO on the gut microbiota in these cohorts was mild.

中文翻译：

---

Levaquin获得通行证。

强化治疗后，抗生素引起的肠道营养不良与不良预后相关。我们评估了左氧氟沙星（LEVO）（强化化疗和同种异体造血细胞移植（allo-HCT）期间最常用的预防性抗生素）对2例患者中1例包括20例接受急性白血病治疗的患者的肠道菌群的影响强化化疗和其他队列研究，包括20名同种HCT接受者。每周三次收集粪便样本进行16S rRNA基因测序，可以比较未接触抗菌素的时间间隔和仅接触LEVO的时间间隔。在混合效应模型中，受LEVO影响的唯一变量是副细菌的相对丰度（回归系数-.063； 99％置信区间[CI]，-。102至-。024）和Blautia（回归系数，.050； 99％CI，.004至.095）。其他类群和微生物群的多样性不受影响。总体而言，在这些人群中，LEVO对肠道菌群的影响是轻微的。